prodchem
Aug 24, 2026
Sun Pharmaceutical Industries has agreed to acquire Organon & Co., the global healthcare company spun off from Merck & Co. in 2021, in an all-cash transaction valued at $11.75 billion in enterprise value. The deal represents Sun Pharma’s largest-ever acquisition and one of the biggest overseas acquisitions by an Indian pharmaceutical company.
Under the agreement, Organon shareholders will receive $14 per share in cash. The transaction is expected to significantly expand Sun Pharma’s global scale while strengthening its position in women’s health, established brands, and biosimilars. The deal remains subject to regulatory and shareholder approvals and is expected to close in early 2027.
Organon was created through a spin-off from Merck in 2021, becoming an independent healthcare company focused primarily on women’s health, biosimilars, and established medicines.
The company has a portfolio of more than 70 products marketed across approximately 140–150 countries, with major markets including the United States, Europe, China, Canada, and Brazil. Organon also operates six manufacturing facilities across the European Union and emerging markets.
For Sun Pharma, acquiring this established global infrastructure offers a faster route to expanding its international presence than building comparable commercial operations organically.
One of the most important strategic benefits of the transaction is Organon’s established position in women's health.
Following completion of the acquisition, Sun Pharma expects the combined business to become a top-three company globally in women's health. This would give Sun Pharma a significantly larger platform in a therapeutic area where Organon already has extensive products, commercial relationships, and market experience.
The acquisition therefore gives Sun Pharma access not only to products but also to an established global commercial platform that can support future product launches and partnerships.
Biosimilars are another major attraction of the transaction.
Organon's portfolio includes biosimilars alongside its established medicines business. Through the acquisition, Sun Pharma expects to become the seventh-largest biosimilar company globally.
This is strategically important because biosimilars represent a growing segment of the pharmaceutical industry as healthcare systems seek more affordable alternatives to complex biologic medicines.
Sun Pharma's entry at this scale could provide the company with a stronger platform for competing in global biologics markets and expanding its presence in highly regulated pharmaceutical segments.
The acquisition would significantly broaden Sun Pharma's international commercial reach.
The combined company is expected to generate approximately $12.4 billion in revenue and rank among the top 25 pharmaceutical companies globally. Sun Pharma also expects to have operations across approximately 150 countries, with 18 large markets generating more than $100 million each in revenue.
This geographic diversification could reduce the company's dependence on individual markets while giving it greater access to emerging and developed pharmaceutical markets.
The strategic rationale behind the acquisition is based on the complementary nature of the two companies.
Sun Pharma has built a strong position in generics and specialty medicines, while Organon brings established brands, women's health products, biosimilars, and a broad international commercial infrastructure.
The combination could allow Sun Pharma to diversify its revenue base while increasing the contribution of innovative and specialty-oriented products. The companies have said the combined business is expected to have 27% of revenue coming from Sun Pharma's Innovative Medicines portfolio.
At an enterprise value of $11.75 billion, the Organon acquisition is a transformational transaction for Sun Pharma.
The $14-per-share offer represents a substantial premium to Organon's pre-announcement trading price. The transaction is structured as an all-cash acquisition, with Organon shareholders receiving the agreed cash consideration once the transaction closes.
For Sun Pharma, the size of the investment also means that successful integration, cost management, and realization of expected strategic benefits will be important to generating long-term value from the deal.
The acquisition is significant beyond Sun Pharma because it highlights the increasing importance of scale and portfolio diversification in global pharmaceuticals.
Established pharmaceutical companies are increasingly looking for opportunities to expand into high-growth therapeutic areas, strengthen international distribution networks, and build capabilities in complex products such as biosimilars.
Sun Pharma's acquisition of Organon demonstrates how an Indian pharmaceutical company can use a major cross-border transaction to move further into the global pharmaceutical mainstream.
The deal also reflects continuing consolidation across the pharmaceutical industry as companies seek established products and commercial infrastructure rather than relying entirely on lengthy internal development programs.
Despite its strategic advantages, the transaction also presents several challenges.
Integrating two large pharmaceutical organizations operating across multiple countries will require careful management. Sun Pharma will need to maintain business continuity while aligning commercial operations, manufacturing networks, regulatory processes, and corporate systems.
The company will also need to manage the financial implications of such a large acquisition and ensure that Organon's portfolio continues to perform while new growth opportunities are developed.
The transaction's expected early-2027 closing also means that regulatory approvals and Organon shareholder approval remain important milestones before the acquisition can be completed.
If successfully completed, the Organon acquisition could transform Sun Pharma's global profile.
The company would gain:
A substantially larger women's health business
A major position in global biosimilars
More than 70 established products
A commercial presence across approximately 150 countries
Additional manufacturing capabilities
Greater exposure to established international brands
A combined revenue base of approximately $12.4 billion
These additions could provide Sun Pharma with a more diversified platform for future growth.
Sun Pharma's proposed $11.75 billion acquisition of Organon represents a landmark transaction for the Indian pharmaceutical industry and the largest deal in Sun Pharma's history.
By acquiring the former Merck spin-off, Sun Pharma would significantly strengthen its global presence while gaining major positions in women's health, biosimilars, and established medicines. The combined company is expected to rank among the world's top 25 pharmaceutical companies and become a top-three player in global women's health.
The transaction still requires regulatory and shareholder approvals, but if completed as planned in early 2027, it could mark a major transformation of Sun Pharma from a leading Indian pharmaceutical company into an even more diversified global healthcare player.
Featured Product
Found this useful?
Continue Reading
Revvity's $72 million ACD/Labs acquisition highlights a focused software M&A strategy aimed at strengthening scientific data, analytical workflows and AI-ready R&D infrastructure across pharmaceutical, biotech and chemical markets.
HSH Chemie's acquisition adds international market access to its established fructose expertise, strengthening its ability to participate in cross-border sweetener trade. The transaction highlights how specialty ingredient acquisitions can expand distribution reach and sourcing opportunities.
Chemours' May 2026 EPA agreement adds another significant PFAS settlement to the chemical industry's growing regulatory record, highlighting the rising financial, compliance and supply-chain implications of long-term environmental liabilities.
